Yanjun Hou to Receptor, erbB-2
This is a "connection" page, showing publications Yanjun Hou has written about Receptor, erbB-2.
Connection Strength
2.856
-
Hou Y, Nitta H, Parwani AV, Li Z. PD-L1 and CD8 are associated with deficient mismatch repair status in triple-negative and HER2-positive breast cancers. Hum Pathol. 2019 Apr; 86:108-114.
Score: 0.632
-
Hou Y, Nitta H, Wei L, Banks PM, Lustberg M, Wesolowski R, Ramaswamy B, Parwani AV, Li Z. PD-L1 expression and CD8-positive T cells are associated with favorable survival in HER2-positive invasive breast cancer. Breast J. 2018 Nov; 24(6):911-919.
Score: 0.619
-
Hou Y, Nitta H, Wei L, Banks PM, Portier B, Parwani AV, Li Z. HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma. Breast Cancer Res Treat. 2017 Nov; 166(2):447-457.
Score: 0.573
-
Hou Y, Nitta H, Li Z. HER2 Gene Protein Assay Is Useful to Determine HER2 Status and Evaluate HER2 Heterogeneity in HER2 Equivocal Breast Cancer. Am J Clin Pathol. 2017 Jan 01; 147(1):89-95.
Score: 0.550
-
Hou Y, Peng Y, Li Z. Update on prognostic and predictive biomarkers of breast cancer. Semin Diagn Pathol. 2022 Sep; 39(5):322-332.
Score: 0.201
-
Hou Y, Nitta H, Wei L, Banks PM, Parwani AV, Li Z. Evaluation of Immune Reaction and PD-L1 Expression Using Multiplex Immunohistochemistry in HER2-Positive Breast Cancer: The Association With Response to Anti-HER2 Neoadjuvant Therapy. Clin Breast Cancer. 2018 Apr; 18(2):e237-e244.
Score: 0.146
-
Hou Y, Shen R, Chaudhary S, Gao F, Li Z. Correlation of Expression of Breast Biomarkers in Primary and Metastatic Breast Carcinomas: A Single-Institution Experience. Acta Cytol. 2016; 60(5):481-489.
Score: 0.135